This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX)

Tipranks - Tipranks - Wed Jun 10, 6:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX).

Introducing TipRanks MCP for Agents

Incyte (INCY)

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Incyte today. The company’s shares closed last Monday at $100.64.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 17.2% and a 56.9% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Aveanna Healthcare Holdings, and Protagonist Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.06 average price target, a 7.1% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Nuvalent (NUVL)

Truist Financial analyst Gregory Renza maintained a Buy rating on Nuvalent today. The company’s shares closed last Monday at $88.49.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 14.3% and a 43.1% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $141.60 average price target, a 56.5% upside from current levels. In a report issued on May 26, LifeSci Capital also maintained a Buy rating on the stock with a $142.00 price target.

Viking Therapeutics (VKTX)

William Blair analyst Andy Hsieh reiterated a Buy rating on Viking Therapeutics today. The company’s shares closed last Monday at $29.24, close to its 52-week low of $24.41.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 7.5% and a 42.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Aardvark Therapeutics, Inc., and Corbus Pharmaceuticals. ;'>

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $93.70, representing a 225.9% upside. In a report issued on May 27, Truist Financial also initiated coverage with a Buy rating on the stock with a $83.00 price target.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).